98%
921
2 minutes
20
Noninvasive treatment of inflammatory bowel disease with lower gastrointestinal bleeding is a major clinical challenge. In this study, we designed an orally targeted microsphere based on sunflower pollen microcapsules to localize the site of inflammatory injury and promote hemostasis and tissue repair. Due to the Eudragit and ascorbate palmitate coatings, EL/AP@PS(t+Dex) demonstrates pH- and enzyme-responsive release of loaded drugs and helps to resist the harsh environment of the gastrointestinal tract. Both in vitro and in vivo experiments show the characteristics of inflammation targeting and mucosal adhesion, which reduce the systematic exposure and increase the local drug concentration. In the DSS model, orally administered EL/AP@PS(t+Dex) significantly alleviates hematochezia, inhabits intestinal inflammation, and remarkably promotes the recovery of the intestinal epithelial barrier to reduce the exposure of intestinal microvessels. Furthermore, EL/AP@PS(t+Dex) optimized the composition of intestinal microbiota, which benefits intestinal homeostasis. This finding provides a fundamental solution for the treatment of intestinal bleeding caused by inflammatory bowel disease (IBD).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsami.4c02408 | DOI Listing |
Clin J Gastroenterol
September 2025
Department of Gastroenterology, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita City, Akita, Japan.
Primary gastric squamous cell carcinoma (GSCC) or gastric adenosquamous carcinoma (GASC) is an uncommon histologic type for which no standard treatment has been established. The prognosis is poor, and there are few reports of effective treatment. Here, we experienced a case of GASC that was diagnosed preoperatively as GSCC and could be operated on after successful preoperative chemotherapy with pembrolizumab, 5-fluorouracil, and cisplatin.
View Article and Find Full Text PDFNihon Shokakibyo Gakkai Zasshi
January 2025
Division of Inflammatory Bowel Disease Surgery, Department of Gastroenterological Surgery, Hyogo Medical University.
Gastroenterol Hepatol
September 2025
Inflammatory Bowel Disease Unit, Gastroenterology Department, Institut de Recerca Sant Pau (IR-SantPau), Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain.
Objective: Chlamydia trachomatis is a prevalent cause of infectious proctitis, often misdiagnosed as cancer or inflammatory bowel disease (IBD). This study aims to describe the main clinical symptoms, together with endoscopic and histopathological characteristics of Chlamydia trachomatis proctitis in the general population.
Patients And Methods: A retrospective observational study was conducted at a single institution, identifying all cases of proctitis due to Chlamydia trachomatis infection, detected by real-time PCR in rectal biopsy or anal smear, with endoscopic assessment.
Clin Gastroenterol Hepatol
September 2025
Inflammatory Bowel Disease Center at NYU Langone Health, 305 East 33(rd) Street, New York, NY 10016. Electronic address:
Clin Gastroenterol Hepatol
September 2025
Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Gastroenterology Unit, Azienda Ospedale Università Padova, Padua, Italy. Electronic address:
Background And Aims: Topical corticosteroids represent one of the effective first-line treatment options for EoE, and therapy with budesonide orodispersible tablets (BOTs) has been recently approved for the treatment of EoE and showed great efficacy in randomized-controlled clinical trials, however real-life data is lacking. Thus, we aimed to evaluate the effectiveness of treatment with BOTs in adult EoE patients in a real-life setting.
Methods: In this prospective study, clinical, histologic, endoscopic, and safety measures were assessed.